Orexo’s Treatment for Incontinence/Nocturia Entering Phase I

Orexo’s product for nocturia and on demand treatment of urinary incontinence, OX 19 has started Phase I trials.

Orexo said it has developed several formulations and is now proceeding to investigate the lead formulation. The bioavailability trial for OX 19 (sublingual desmopressin), which is taking place in Sweden, is expected to be completed by the end of this year.

The company added that OX 19 uses novel sublingual tablet technology the enables rapid and reliable onset of action.